MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Metrics to compare | MTVA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMTVAPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.2x | −3.4x | −0.5x | |
PEG Ratio | −0.01 | 0.00 | 0.00 | |
Price/Book | 1.4x | 1.8x | 2.6x | |
Price / LTM Sales | - | 25.6x | 2.9x | |
Upside (Analyst Target) | - | 200.3% | 49.4% | |
Fair Value Upside | Unlock | −2.8% | 8.2% | Unlock |